Sutro Biopharma Ownership
| STRO Stock | USD 3.73 0.02 0.54% |
Shares in Circulation | First Issued 2017-09-30 | Previous Quarter 61.5 M | Current Value 81.2 M | Avarage Shares Outstanding 38.6 M | Quarterly Volatility 19.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Sutro |
Sutro Stock Ownership Analysis
About 78.0% of the company shares are owned by institutional investors. The book value of Sutro Biopharma was at this time reported as 1.86. The company has Price/Earnings To Growth (PEG) ratio of 0.12. Sutro Biopharma recorded a loss per share of 1.78. The entity had not issued any dividends in recent years. Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. Sutro Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people. To find out more about Sutro Biopharma contact William JD at 650 881 6500 or learn more at https://www.sutrobio.com.Besides selling stocks to institutional investors, Sutro Biopharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Sutro Biopharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Sutro Biopharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Sutro Biopharma Quarterly Liabilities And Stockholders Equity |
|
Sutro Biopharma Insider Trades History
Less than 1% of Sutro Biopharma are currently held by insiders. Unlike Sutro Biopharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Sutro Biopharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Sutro Biopharma's insider trades
Sutro Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sutro Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sutro Biopharma backward and forwards among themselves. Sutro Biopharma's institutional investor refers to the entity that pools money to purchase Sutro Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Eversept Partners, Llc | 2024-06-30 | 1.7 M | Geode Capital Management, Llc | 2024-06-30 | 1.7 M | Citadel Advisors Llc | 2024-06-30 | 1.6 M | State Street Corp | 2024-06-30 | 1.6 M | Dimensional Fund Advisors, Inc. | 2024-06-30 | 1.1 M | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 1.1 M | Goldman Sachs Group Inc | 2024-06-30 | 1 M | Panagora Asset Management Inc | 2024-06-30 | 907.5 K | Nuveen Asset Management, Llc | 2024-06-30 | 905.4 K | Suvretta Capital Management, Llc | 2024-06-30 | 7.7 M | Blackrock Inc | 2024-06-30 | 6.9 M |
Sutro Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sutro Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sutro Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sutro Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sutro Biopharma Outstanding Bonds
Sutro Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sutro Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sutro bonds can be classified according to their maturity, which is the date when Sutro Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Sutro Biopharma Corporate Filings
F4 | 20th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 12th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 10th of July 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 17th of May 2024 Other Reports | ViewVerify |
Pair Trading with Sutro Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Sutro Stock
The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Revenue Per Share 2.563 | Quarterly Revenue Growth 1.469 | Return On Assets (0.14) | Return On Equity (0.81) |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.